ASH20: Out to shake up CML once again, Novartis lays out head-to-head between third-gen Gleevec scion and Pfizer rival

Novartis says its third-generation chronic myeloid leukemia drug — a scion to the fading blockbuster Gleevec — nearly doubled the response rate among patients who have progressed after two lines of treatment, paving the way to shake up the space once again.